Hydrogen Sulfide and Heart Failure
Despite the abundance of medications to lower blood pressure, reduce cholesterol, and treat cardiovascular conditions, cardiovascular disease remains the number one killer in the US. Further, the incidence of heart failure is projected to increase by 25% over the next 20 years with a projected cost of $69.7 billion representing a substantial health and economic burden on the US.
In addition, work carried out in the laboratories of Dr. Lefer and Dr. Elrod showed that SG1002 reduces myocardial infarct size, prevents deficits in left ventricular function (ejection fraction recovery), promotes favorable left ventricular remodeling and reduces pulmonary edema.
*Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, Calvert JW. Hydrogen Sulfide Attenuates Cardiac Dysfunction After Heart Failure via Induction of Angiogenesis. Circ Heart Fail. 2013 Sep 1;6(5):1077-86.
Originally published in PNAS 2007. Read Article
Hydrogen sulfide is a recognized endogenous signaling molecule that has been shown to modulate mitochondrial function, act as an antioxidant, and increase blood flow by a variety of mechanisms. In addition, hydrogen sulfide is a potent anti-inflammatory agent and modulator of cell death. This plethora of cytoprotective properties makes it an ideal candidate for the treatment of cardiovascular disease.
Importantly, studies of heart failure patients have demonstrated an inverse correlation between the levels of circulating hydrogen sulfide and the degree of heart failure. Thus, a product that increases circulating levels of hydrogen sulfide may be able to overcome this deficit.